SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Swedish drug developer IRLAB's Q3 sales fall sharply, cash flow turns negative

OverviewOutlookResult DriversCompany press release:Key DetailsAnalyst CoverageReuters Recommended ReadsFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using…

IRLABA
SquawkNews Desk

Related stories

Lilly Phase 3 Trial Reports Average 21.4% BMI Reduction With Zepbound The SURMOUNT-ADOLESCENTS trial showed Zepbound reduced BMI by an average of 21.4% in adolescents aged 12 to under 18 with obesity. M impact | EQUITY | Nov 14, 2026, 05:01 PM UTC Lilly Phase 2 Data Show Eloratzp Weight Loss of Up to 54.1 Pounds Phase 2 data showed average weight loss of up to 54.1 pounds (23.3%) at 48 weeks in adults with obesity and type 2 diabetes. M impact | EQUITY | Nov 14, 2026, 05:01 PM UTC Novo Nordisk CagriSema Reduced Waist Circumference by 17.2–17.5 cm Both CagriSema doses reduced waist circumference by 17.2–17.5 cm, versus 3.6 cm with placebo. M impact | EQUITY | Nov 14, 2026, 05:00 PM UTC Novo Nordisk CagriSema Shows Weight Loss in REDEFINE 9 Trial At 68 weeks, average weight loss was 20.7% with 1.7 mg/1.7 mg and 21.0% with 1.0 mg/1.0 mg, versus 2.0% with placebo. M impact | EQUITY | Nov 14, 2026, 05:00 PM UTC Novo Nordisk Says CagriSema Reduced Waist Circumference Up to 17.5 cm Both CagriSema doses reduced waist circumference by 17.2–17.5 cm, versus 3.6 cm with placebo. M impact | EQUITY | Nov 14, 2026, 05:00 PM UTC DUFFY: WE NEED L3HARRIS OR WHOEVER PROVIDED ROUTER TO DO A BETTER JOB L impact | EQUITY | Nov 14, 2026, 04:32 PM UTC